Exelixis Inc (EXEL) 8.15 $EXEL
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.62 (+0.16), ARIA: 7.51 (+0.17), CELG: 105.03 (+0.62), EXEL: 8.15 (+0.01), CELGZ: 1.43 (+0.08)
InvestorsObserver releases covered-call reports for 3D Systems, Exelixis, Caterpillar Inc., Barrick Gold Corporation and Priceline
PR Newswire - Tue Jul 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABX, CAT, DDD, EXEL, and PCLN.
ABX: 22.32 (-0.03), DDD: 14.12 (+0.66), CAT: 77.37 (+2.32), PCLN: 1,329.46 (+32.20), EXEL: 8.15 (+0.01)
Exelixis Set to Possibly Pullback After Yesterday's Rally of 3.39%
Comtex SmarTrend(R) - Fri Jul 01, 12:48PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $7.81 to a high of $8.15. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $7.90 on volume of 15.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 8.15 (+0.01)
Merger & Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizer's $5.2 Billion Purchase
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The Biotech Industry received a boost last month after Pfizer Inc. announced its acquisition of Anacor Pharmaceuticals Inc. and its eczema gel, crisaborole, for $5.2 billion. Under the terms of the deal, Pfizer agreed to pay $99.25 per share in cash for Anacor, which represented a 55 percent premium to Anacor's closing price of $64.03 on May 13th. The transaction has already received approval from both the company's board of directors and is expected to be completed in the third quarter of 2016. The acquisition could potentially kick start merger and acquisition activity within the biotech industry as larger pharmaceutical and biotech companies will also look to boost revenues through acquisitions. Register with us now for your free membership and gain access to our biotech reports at: www.rdinvesting.com. Today we feature reports on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Exelixis, Inc. (NASDAQ: EXEL), Medivation Inc. (NASDAQ: MDVN) and Novavax, Inc. (NASDAQ: NVAX).
MDVN: 62.10 (-0.64), ACAD: 34.62 (+1.11), NVAX: 7.62 (+0.16), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14), EXEL: 8.15 (+0.01)
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 8:30AM CDT
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
LXP: 10.23 (+0.24), HL: 6.05 (+0.39), ARCO: 4.89 (+0.03), CORT: 6.01 (+0.14), EXEL: 8.15 (+0.01)
Explosive Stocks Under $10
Kevin Matras - ZACKS - Tue Jun 28, 2:27PM CDT
Explosive Stocks Under $10
LXP: 10.23 (+0.24), HL: 6.05 (+0.39), ARCO: 4.89 (+0.03), CORT: 6.01 (+0.14), EXEL: 8.15 (+0.01)
Exelixis Has Returned 58.9% Since SmarTrend Recommendation (EXEL)
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 2 months, Exelixis has returned 58.94% as of today's recent price of $7.82.
EXEL: 8.15 (+0.01)
Exelixis Shares Up 50.0% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Thu Jun 16, 12:23AM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 2 months, Exelixis has returned 50.00% as of today's recent price of $7.38.
EXEL: 8.15 (+0.01)
Exelixis Shares Up 45.1% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Wed Jun 08, 12:57PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 1 month, Exelixis has returned 45.12% as of today's recent price of $7.14.
EXEL: 8.15 (+0.01)
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), PFE: 36.12 (+0.35), EXEL: 8.15 (+0.01)
Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:15AM CDT
Exelixis, Inc. (EXEL) shares rose over 11% in the last trading session.
ANIP: 56.51 (-1.61), EXEL: 8.15 (+0.01)
Roche Presents Encouraging Data on Actemra and Tecentriq
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:49PM CDT
Roche Holding AG (RHHBY) announced positive results from the phase III study, GiACTA, on arthritis drug, Actemra/RoActemra.
PFE: 36.12 (+0.35), BMY: 75.28 (+1.20), EXEL: 8.15 (+0.01)
SmarTrend Watching for Potential Pullback in Shares of Exelixis After 8.35% Gain
Comtex SmarTrend(R) - Mon Jun 06, 2:44PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.76 to a high of $7.34. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $6.80 on volume of 10.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 8.15 (+0.01)
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX(TM) (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 6:36AM CDT
--ABSTRACT #4557, #4558
EXEL: 8.15 (+0.01)
Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX(TM) (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO
BusinessWire - Sun Jun 05, 6:53AM CDT
--- Overall survival and progression-free survival benefits consistent across all subgroups evaluated -
EXEL: 8.15 (+0.01)
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX(TM) (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
BusinessWire - Sun Jun 05, 6:36AM CDT
--Overall survival and progression-free survival benefits consistent across all subgroups evaluated
EXEL: 8.15 (+0.01)
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
BusinessWire - Sun Jun 05, 6:30AM CDT
--- Phase 3 pivotal trial of combination has been initiated -
EXEL: 8.15 (+0.01)
Exelixis Rises 4.27% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 3:16PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.46 to a high of $6.80. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $6.63 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 8.15 (+0.01)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.62 (+0.16), ARIA: 7.51 (+0.17), CELG: 105.03 (+0.62), EXEL: 8.15 (+0.01), CELGZ: 1.43 (+0.08)
InvestorsObserver releases covered-call reports for 3D Systems, Exelixis, Caterpillar Inc., Barrick Gold Corporation and Priceline
PR Newswire - Tue Jul 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABX, CAT, DDD, EXEL, and PCLN.
ABX: 22.32 (-0.03), DDD: 14.12 (+0.66), CAT: 77.37 (+2.32), PCLN: 1,329.46 (+32.20), EXEL: 8.15 (+0.01)
Exelixis Set to Possibly Pullback After Yesterday's Rally of 3.39%
Comtex SmarTrend(R) - Fri Jul 01, 12:48PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $7.81 to a high of $8.15. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $7.90 on volume of 15.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 8.15 (+0.01)
Merger & Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizer's $5.2 Billion Purchase
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The Biotech Industry received a boost last month after Pfizer Inc. announced its acquisition of Anacor Pharmaceuticals Inc. and its eczema gel, crisaborole, for $5.2 billion. Under the terms of the deal, Pfizer agreed to pay $99.25 per share in cash for Anacor, which represented a 55 percent premium to Anacor's closing price of $64.03 on May 13th. The transaction has already received approval from both the company's board of directors and is expected to be completed in the third quarter of 2016. The acquisition could potentially kick start merger and acquisition activity within the biotech industry as larger pharmaceutical and biotech companies will also look to boost revenues through acquisitions. Register with us now for your free membership and gain access to our biotech reports at: www.rdinvesting.com. Today we feature reports on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Exelixis, Inc. (NASDAQ: EXEL), Medivation Inc. (NASDAQ: MDVN) and Novavax, Inc. (NASDAQ: NVAX).
MDVN: 62.10 (-0.64), ACAD: 34.62 (+1.11), NVAX: 7.62 (+0.16), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14), EXEL: 8.15 (+0.01)
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 8:30AM CDT
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
LXP: 10.23 (+0.24), HL: 6.05 (+0.39), ARCO: 4.89 (+0.03), CORT: 6.01 (+0.14), EXEL: 8.15 (+0.01)
Explosive Stocks Under $10
Kevin Matras - ZACKS - Tue Jun 28, 2:27PM CDT
Explosive Stocks Under $10
LXP: 10.23 (+0.24), HL: 6.05 (+0.39), ARCO: 4.89 (+0.03), CORT: 6.01 (+0.14), EXEL: 8.15 (+0.01)
Exelixis Has Returned 58.9% Since SmarTrend Recommendation (EXEL)
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 2 months, Exelixis has returned 58.94% as of today's recent price of $7.82.
EXEL: 8.15 (+0.01)
Exelixis Shares Up 50.0% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Thu Jun 16, 12:23AM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 2 months, Exelixis has returned 50.00% as of today's recent price of $7.38.
EXEL: 8.15 (+0.01)
Exelixis Shares Up 45.1% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Wed Jun 08, 12:57PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 1 month, Exelixis has returned 45.12% as of today's recent price of $7.14.
EXEL: 8.15 (+0.01)
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), PFE: 36.12 (+0.35), EXEL: 8.15 (+0.01)
Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:15AM CDT
Exelixis, Inc. (EXEL) shares rose over 11% in the last trading session.
ANIP: 56.51 (-1.61), EXEL: 8.15 (+0.01)
Roche Presents Encouraging Data on Actemra and Tecentriq
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:49PM CDT
Roche Holding AG (RHHBY) announced positive results from the phase III study, GiACTA, on arthritis drug, Actemra/RoActemra.
PFE: 36.12 (+0.35), BMY: 75.28 (+1.20), EXEL: 8.15 (+0.01)
SmarTrend Watching for Potential Pullback in Shares of Exelixis After 8.35% Gain
Comtex SmarTrend(R) - Mon Jun 06, 2:44PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.76 to a high of $7.34. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $6.80 on volume of 10.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 8.15 (+0.01)
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX(TM) (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 6:36AM CDT
--ABSTRACT #4557, #4558
EXEL: 8.15 (+0.01)
Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX(TM) (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO
BusinessWire - Sun Jun 05, 6:53AM CDT
--- Overall survival and progression-free survival benefits consistent across all subgroups evaluated -
EXEL: 8.15 (+0.01)
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX(TM) (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
BusinessWire - Sun Jun 05, 6:36AM CDT
--Overall survival and progression-free survival benefits consistent across all subgroups evaluated
EXEL: 8.15 (+0.01)
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
BusinessWire - Sun Jun 05, 6:30AM CDT
--- Phase 3 pivotal trial of combination has been initiated -
EXEL: 8.15 (+0.01)
Exelixis Rises 4.27% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 3:16PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.46 to a high of $6.80. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $6.63 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 8.15 (+0.01)
